Pharmacogenetic Biomarker Discovery, Personalized Medicine, and Clinical Test Commercialization in Neuropsychiatry

Pharmacotherapy is one of the primary treatments for psychiatric disorders. Given the variation in individual response, and the current trial-and-error treatment, a more personalized approach is needed. The Mitacs Elevate postdoctoral trainee will gain direct experience with all aspects of using pharmacogenetic testing to personalize medication prescriptions for patients, and the commercialization of the test. Our Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) project is a partnership between the University of Toronto CAMH hospital and Assurex Health Ltd for test delivery and commercialization. The goal of IMPACT is to increase the success rate of drug response and medication adherence, and to limit the risk of side effects from medications. IMPACT aims to improve response through providing guidance (Assurex GeneSight test) to the physician for choosing the type and dosage of medication based on a patient?s genetic makeup. TO BE CONT’D

Faculty Supervisor:

Jim Kennedy

Student:

Julie-Anne Tanner

Partner:

AssureRx Canada

Discipline:

Psychology

Sector:

Medical devices

University:

Program: